Olgu Sunumu

Tailored Treatments: Utilizing Anti-TNFs for Ankylosing Spondylitis and Essential Thrombocytosis

Cilt: 47 Sayı: 1 29 Mart 2025
Cumhuriyet Tıp Dergisi Kapak
Cumhuriyet Tıp Dergisi
PDF İndir
TR EN

Tailored Treatments: Utilizing Anti-TNFs for Ankylosing Spondylitis and Essential Thrombocytosis

Abstract

Thrombocytosis is a condition that is often detected incidentally and can be seen both in the course of myeloproliferative diseases (MPD) and as a reactive condition. Ankylosing spondylitis (AS) is a chronic multisystemic inflammatory disease that mainly affects the spine. Mild to moderate thrombocytosis may occur secondary to the course of AS. In the treatment of AS, tumor necrosis factor inhibitor (anti-TNF) treatments are actively used as first-line therapy. The number of cases of MPDs occurring in the course of AS reported in the literature is limited. Although the exact effect of anti-TNF treatment on the MPD process is not fully known, there are publications stating that caution should be exercised in cases of MPD. By this case, we wanted to share our experience of using anti-TNF therapy in a patient diagnosed with ET in the course of AS. The 35-year-old male patient had been diagnosed with AS for 11 years and had been followed up by hematology with the diagnosis of essential thrombocytosis (ET) since 2010. When there was no response to indomethacin and sulfasalazine treatments, the patient was first given etanercept, and after secondary unresponsiveness, infliximab and adalimumab treatments were given. Despite the use of multiple anti-TNFs, no hematological deterioration was detected in terms of ET. Clinical and laboratory responses were also obtained in terms of AS. The patient has been stable and in remission in terms of both AS and ET since 2016.

Keywords

Kaynakça

  1. 1. Schafer AI. Thrombocytosis. New England Journal of Medicine. 2004;350(12):1211-9. DOI: 10.1056/NEJMra0353 63
  2. 2. Deng L, Zheng P. Thrombocytosis in patients with spondyloarthritis: a case–control study. BMC Musculoskeletal Disorders. 2023;24(1):195. DOI: 10.1186/ s12891-023-06304-1
  3. 3. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697-718. DOI: 10.1002/ajh.27216
  4. 4. Fischer M, Helper DJ, Chiorean MV. Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: Report of two cases and review of the literature. Inflammatory Bowel Diseases. 2010;17(2):674-5. DOI: 10.1002/ibd.21291
  5. 5. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218-27. doi: 10.1002/art.1780341003.
  6. 6. Ayvaz OC, Yavasoglu I, Kadikoylu G, Bozkurt G, Bolaman Z. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia. Rheumatol Int. 2012;32(1):269-71. doi: 10.1007/s00296-010-1747-0.
  7. 7. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89(2):215-32. PMID: 15003898
  8. 8. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost. 2012;38(5):497-505. doi: 10.1055/s-0032-1306433.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Tıp Eğitimi

Bölüm

Olgu Sunumu

Yazarlar

Erken Görünüm Tarihi

29 Mart 2025

Yayımlanma Tarihi

29 Mart 2025

Gönderilme Tarihi

3 Ocak 2025

Kabul Tarihi

4 Mart 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 47 Sayı: 1

DOI

https://doi.org/10.7197/cmj.1612981

IZ

https://izlik.org/JA56AS27KA

Kaynak Göster

RIS / Bibtex
AMA
1.Bulut Gökten D, Mercan R. Tailored Treatments: Utilizing Anti-TNFs for Ankylosing Spondylitis and Essential Thrombocytosis. CMJ. 2025;47(1):52-54. doi:10.7197/cmj.1612981